Atossa Therapeutics
M$86
301
-M$24-21.82% Monday 18:51
Statistics
Day High
86
Day Low
86
52W High
322.5
52W Low
75
Volume
138
Avg. Volume
54
Mkt Cap
11.11B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
18MayExpected
Expected EPS
-0.923333
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-1.01BNet Income
Analyst Ratings
$224.40Average Price Target
The highest estimate is 340.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ATOS.MX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap140.15B
Merck
MRK
Mkt Cap214.76B
Novartis
NVS
Mkt Cap237.61B
Gilead Sciences
GILD
Mkt Cap148.78B
AMGEN
AMGN
Mkt Cap160.66B
Abbvie
ABBV
Mkt Cap385.18B
Astrazeneca
AZN
Mkt Cap256.58B
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Lilly(Eli) &
LLY
Mkt Cap772.28B
About
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Show more...
CEO
Dr. Steven C. Quay FCAP, M.D., Ph.D.
Employees
6
Country
United States
ISIN
US04962H7044
Listings
0 Comments
Share your thoughts
FAQ
What is Atossa Therapeutics stock price today?▼
The current price of ATOS.MX is M$86 MXN — it has decreased by -21.82% in the past 24 hours. Watch Atossa Therapeutics stock price performance more closely on the chart.
What is Atossa Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Atossa Therapeutics stocks are traded under the ticker ATOS.MX.
What is Atossa Therapeutics market cap?▼
Today Atossa Therapeutics has the market capitalization of 11.11B
When is the next Atossa Therapeutics earnings date?▼
Atossa Therapeutics is going to release the next earnings report on May 18, 2026.
What were Atossa Therapeutics earnings last quarter?▼
ATOS.MX earnings for the last quarter are -21.15 MXN per share, whereas the estimation was -20.22 MXN resulting in a -4.62% surprise. The estimated earnings for the next quarter are N/A MXN per share.
What is Atossa Therapeutics revenue for the last year?▼
Atossa Therapeutics revenue for the last year amounts to 0 MXN.
What is Atossa Therapeutics net income for the last year?▼
ATOS.MX net income for the last year is -1.01B MXN.
How many employees does Atossa Therapeutics have?▼
As of April 01, 2026, the company has 6 employees.
In which sector is Atossa Therapeutics located?▼
Atossa Therapeutics operates in the Healthcare sector.
When did Atossa Therapeutics complete a stock split?▼
Atossa Therapeutics has not had any recent stock splits.
Where is Atossa Therapeutics headquartered?▼
Atossa Therapeutics is headquartered in Seattle, United States.